Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) Stock Competitors & Peer Comparison
See AMRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMRX | $18.14 | +0.39% | 5.8B | 20.16 | $0.90 | N/A |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AMRX vs TAK Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TAK's P/E ratio is 12.55. In terms of profitability, AMRX's ROE is -3.27%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AMRX is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TAK's competition here
Haleon plc (NYSE: HLN)
AMRX vs HLN Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas HLN's P/E ratio is 25.11. In terms of profitability, AMRX's ROE is -3.27%, compared to HLN's ROE of +0.17%. Regarding short-term risk, AMRX is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AMRX vs TEVA Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TEVA trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TEVA's P/E ratio is 12.06. In terms of profitability, AMRX's ROE is -3.27%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AMRX is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
AMRX vs VTRS Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while VTRS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas VTRS's P/E ratio is 6.52. In terms of profitability, AMRX's ROE is -3.27%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AMRX is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AMRX vs ITCI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AMRX's ROE is -3.27%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AMRX is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
AMRX vs CTLT Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AMRX's ROE is -3.27%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AMRX is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AMRX vs ELAN Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ELAN's P/E ratio is 20.86. In terms of profitability, AMRX's ROE is -3.27%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AMRX is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AMRX vs RDY Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while RDY trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas RDY's P/E ratio is 20.01. In terms of profitability, AMRX's ROE is -3.27%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AMRX is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AMRX vs LNTH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas LNTH's P/E ratio is 16.97. In terms of profitability, AMRX's ROE is -3.27%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AMRX is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AMRX vs INDV Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas INDV's P/E ratio is 10.64. In terms of profitability, AMRX's ROE is -3.27%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AMRX is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AMRX vs SUPN Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SUPN's P/E ratio is 15.57. In terms of profitability, AMRX's ROE is -3.27%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AMRX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AMRX vs RGC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas RGC's P/E ratio is -380.99. In terms of profitability, AMRX's ROE is -3.27%, compared to RGC's ROE of -2.32%. Regarding short-term risk, AMRX is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AMRX vs BHC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas BHC's P/E ratio is 1.59. In terms of profitability, AMRX's ROE is -3.27%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AMRX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AMRX vs DCPH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AMRX's ROE is -3.27%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AMRX is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AMRX vs HCM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while HCM trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas HCM's P/E ratio is 4.69. In terms of profitability, AMRX's ROE is -3.27%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AMRX is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AMRX vs AVDL Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AMRX's ROE is -3.27%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, AMRX is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
AMRX vs EMBCV Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AMRX's ROE is -3.27%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AMRX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AMRX vs DVAX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AMRX's ROE is -3.27%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AMRX is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AMRX vs ANIP Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ANIP's P/E ratio is 9.52. In terms of profitability, AMRX's ROE is -3.27%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AMRX is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
AMRX vs PRGO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PRGO's P/E ratio is 5.13. In terms of profitability, AMRX's ROE is -3.27%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AMRX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AMRX vs TARO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TARO's P/E ratio is 30.05. In terms of profitability, AMRX's ROE is -3.27%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AMRX is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AMRX vs HROW Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas HROW's P/E ratio is 449.33. In terms of profitability, AMRX's ROE is -3.27%, compared to HROW's ROE of -0.34%. Regarding short-term risk, AMRX is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AMRX vs PAHC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PAHC's P/E ratio is 11.70. In terms of profitability, AMRX's ROE is -3.27%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AMRX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
AMRX vs ALVO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ALVO's P/E ratio is -11.21. In terms of profitability, AMRX's ROE is -3.27%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, AMRX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AMRX vs ETON Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ETON's P/E ratio is -637.14. In terms of profitability, AMRX's ROE is -3.27%, compared to ETON's ROE of -0.06%. Regarding short-term risk, AMRX is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
AMRX vs CRON Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CRON's P/E ratio is 29.44. In terms of profitability, AMRX's ROE is -3.27%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AMRX is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AMRX vs PCRX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PCRX's P/E ratio is 9.62. In terms of profitability, AMRX's ROE is -3.27%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AMRX is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AMRX vs COLL Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas COLL's P/E ratio is 3.70. In terms of profitability, AMRX's ROE is -3.27%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AMRX is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AMRX vs PETQ Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AMRX's ROE is -3.27%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AMRX is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
AMRX vs AMPH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas AMPH's P/E ratio is 7.09. In terms of profitability, AMRX's ROE is -3.27%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, AMRX is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AMRX vs IRWD Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas IRWD's P/E ratio is 5.54. In terms of profitability, AMRX's ROE is -3.27%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AMRX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
AMRX vs EVO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas EVO's P/E ratio is -2.82. In terms of profitability, AMRX's ROE is -3.27%, compared to EVO's ROE of -0.24%. Regarding short-term risk, AMRX is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AMRX vs BDSI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AMRX's ROE is -3.27%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AMRX is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AMRX vs TLRY Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TLRY's P/E ratio is -7.21. In terms of profitability, AMRX's ROE is -3.27%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, AMRX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
AMRX vs EOLS Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas EOLS's P/E ratio is -24.04. In terms of profitability, AMRX's ROE is -3.27%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AMRX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AMRX vs AQST Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas AQST's P/E ratio is -6.46. In terms of profitability, AMRX's ROE is -3.27%, compared to AQST's ROE of +1.91%. Regarding short-term risk, AMRX is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
AMRX vs KMDA Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas KMDA's P/E ratio is 20.77. In terms of profitability, AMRX's ROE is -3.27%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AMRX is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AMRX vs CGC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CGC's P/E ratio is -0.58. In terms of profitability, AMRX's ROE is -3.27%, compared to CGC's ROE of -0.31%. Regarding short-term risk, AMRX is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AMRX vs TKNO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TKNO's P/E ratio is -20.84. In terms of profitability, AMRX's ROE is -3.27%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AMRX is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AMRX vs ALIM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AMRX's ROE is -3.27%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AMRX is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
AMRX vs LNDC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AMRX's ROE is -3.27%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AMRX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
AMRX vs EMBC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas EMBC's P/E ratio is 1.70. In terms of profitability, AMRX's ROE is -3.27%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, AMRX is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AMRX vs ORGO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ORGO's P/E ratio is 62.00. In terms of profitability, AMRX's ROE is -3.27%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, AMRX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
AMRX vs TYHT Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AMRX's ROE is -3.27%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AMRX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AMRX vs SIGA Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SIGA's P/E ratio is 11.30. In terms of profitability, AMRX's ROE is -3.27%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AMRX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AMRX vs LFCR Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas LFCR's P/E ratio is -4.68. In terms of profitability, AMRX's ROE is -3.27%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, AMRX is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AMRX vs ACB Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ACB's P/E ratio is -6.10. In terms of profitability, AMRX's ROE is -3.27%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AMRX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AMRX vs REPH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas REPH's P/E ratio is -8.04. In terms of profitability, AMRX's ROE is -3.27%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AMRX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
AMRX vs DERM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas DERM's P/E ratio is -17.38. In terms of profitability, AMRX's ROE is -3.27%, compared to DERM's ROE of -0.36%. Regarding short-term risk, AMRX is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AMRX vs CRDL Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CRDL's P/E ratio is -5.05. In terms of profitability, AMRX's ROE is -3.27%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, AMRX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AMRX vs THTX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas THTX's P/E ratio is -28.83. In terms of profitability, AMRX's ROE is -3.27%, compared to THTX's ROE of +0.17%. Regarding short-term risk, AMRX is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AMRX vs ASRT Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AMRX's ROE is -3.27%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AMRX is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
AMRX vs OGI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas OGI's P/E ratio is -3.81. In terms of profitability, AMRX's ROE is -3.27%, compared to OGI's ROE of -0.07%. Regarding short-term risk, AMRX is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AMRX vs CPIX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CPIX's P/E ratio is -19.50. In terms of profitability, AMRX's ROE is -3.27%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AMRX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AMRX vs SCTL Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AMRX's ROE is -3.27%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AMRX is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
AMRX vs PROC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PROC's P/E ratio is 1.53. In terms of profitability, AMRX's ROE is -3.27%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AMRX is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AMRX vs OPTN Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AMRX's ROE is -3.27%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AMRX is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AMRX vs ZOM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AMRX's ROE is -3.27%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AMRX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AMRX vs ZYBT Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, AMRX's ROE is -3.27%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, AMRX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
AMRX vs GRVI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AMRX's ROE is -3.27%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, AMRX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AMRX vs ZYNE Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AMRX's ROE is -3.27%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AMRX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AMRX vs SSIC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AMRX's ROE is -3.27%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AMRX is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AMRX vs VLNS Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AMRX's ROE is -3.27%, compared to VLNS's ROE of N/A. Regarding short-term risk, AMRX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
AMRX vs BGM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas BGM's P/E ratio is -1.04. In terms of profitability, AMRX's ROE is -3.27%, compared to BGM's ROE of -0.07%. Regarding short-term risk, AMRX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
AMRX vs DRRX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AMRX's ROE is -3.27%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, AMRX is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
AMRX vs INCR Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas INCR's P/E ratio is -2.26. In terms of profitability, AMRX's ROE is -3.27%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AMRX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AMRX vs JUPW Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AMRX's ROE is -3.27%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, AMRX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AMRX vs QLI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas QLI's P/E ratio is -4.92. In terms of profitability, AMRX's ROE is -3.27%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AMRX is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
AMRX vs HEXO Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AMRX's ROE is -3.27%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AMRX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
AMRX vs TLPH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TLPH's P/E ratio is -4.61. In terms of profitability, AMRX's ROE is -3.27%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, AMRX is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AMRX vs RMTI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas RMTI's P/E ratio is -6.89. In terms of profitability, AMRX's ROE is -3.27%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, AMRX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AMRX vs AYTU Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas AYTU's P/E ratio is -1.23. In terms of profitability, AMRX's ROE is -3.27%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, AMRX is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AMRX vs TXMD Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas TXMD's P/E ratio is 105.45. In terms of profitability, AMRX's ROE is -3.27%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, AMRX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AMRX vs CYTH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AMRX's ROE is -3.27%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AMRX is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AMRX vs EVOK Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AMRX's ROE is -3.27%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, AMRX is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
AMRX vs BFRIW Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, AMRX's ROE is -3.27%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, AMRX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AMRX vs OPTH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas OPTH's P/E ratio is -18.56. In terms of profitability, AMRX's ROE is -3.27%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, AMRX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AMRX vs ACRX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AMRX's ROE is -3.27%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, AMRX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
AMRX vs COSM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas COSM's P/E ratio is -0.38. In terms of profitability, AMRX's ROE is -3.27%, compared to COSM's ROE of -0.96%. Regarding short-term risk, AMRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AMRX vs AGRX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AMRX's ROE is -3.27%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AMRX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AMRX vs NLTX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AMRX's ROE is -3.27%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, AMRX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AMRX vs LCI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas LCI's P/E ratio is -0.04. In terms of profitability, AMRX's ROE is -3.27%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AMRX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AMRX vs ADMP Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AMRX's ROE is -3.27%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AMRX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
AMRX vs YCBD Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas YCBD's P/E ratio is -1.38. In terms of profitability, AMRX's ROE is -3.27%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AMRX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AMRX vs GELS Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas GELS's P/E ratio is -1.09. In terms of profitability, AMRX's ROE is -3.27%, compared to GELS's ROE of -0.25%. Regarding short-term risk, AMRX is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
AMRX vs MNK Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas MNK's P/E ratio is -0.44. In terms of profitability, AMRX's ROE is -3.27%, compared to MNK's ROE of -0.26%. Regarding short-term risk, AMRX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AMRX vs FLGC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AMRX's ROE is -3.27%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AMRX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AMRX vs CPHI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CPHI's P/E ratio is -1.76. In terms of profitability, AMRX's ROE is -3.27%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, AMRX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AMRX vs UPC Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while UPC trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas UPC's P/E ratio is -0.69. In terms of profitability, AMRX's ROE is -3.27%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AMRX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
AMRX vs SBFM Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SBFM's P/E ratio is -0.20. In terms of profitability, AMRX's ROE is -3.27%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, AMRX is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AMRX vs SHPH Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SHPH's P/E ratio is -0.20. In terms of profitability, AMRX's ROE is -3.27%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, AMRX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AMRX vs PLXP Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AMRX's ROE is -3.27%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AMRX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AMRX vs SNOA Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas SNOA's P/E ratio is -1.22. In terms of profitability, AMRX's ROE is -3.27%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, AMRX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
AMRX vs ATNX Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AMRX's ROE is -3.27%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AMRX is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
AMRX vs PROCW Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas PROCW's P/E ratio is N/A. In terms of profitability, AMRX's ROE is -3.27%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, AMRX is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
AMRX vs RDHL Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas RDHL's P/E ratio is 0.12. In terms of profitability, AMRX's ROE is -3.27%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, AMRX is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
AMRX vs YCBD-PA Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, AMRX's ROE is -3.27%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, AMRX is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
AMRX vs CYTHW Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas CYTHW's P/E ratio is N/A. In terms of profitability, AMRX's ROE is -3.27%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, AMRX is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
AMRX vs LSDI Comparison August 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.8B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, AMRX is priced at $18.14 on the NASDAQ, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 20.16, whereas LSDI's P/E ratio is -0.07. In terms of profitability, AMRX's ROE is -3.27%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, AMRX is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LSDI's competition here